- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: May 2021
- Public Summary Document (PSD) May 2021 PBAC Meeting - (PDF 1.9MB)
- Public Summary Document (PSD) May 2021 PBAC Meeting - (Word 408KB)
Elexacaftor + tezacaftor + ivacaftor – May 2021
Elexacaftor+ tezacaftor + ivacaftor: Pack containing 56 tablets of elexacaftor 100 mg with tezacaftor 50 mg and ivacaftor 75 mg and 28 tablets of ivacaftor 150 mg; Trikafta®
Last updated
10 September 2021